

16:16-16:22

ICCS S2-2 (LO)

SOLIFENACIN IN CHILDREN AND ADOLESCENTS WITH OVERACTIVE BLADDER: RESULTS OF A PHASE 3 CLINICAL TRIAL

Donald NEWGREEN¹, Brigitte BOSMAN¹, Will SAWYER², Adriana HOLLESTEIN-HAVELAAR³, Robin BESUYEN³, Ellen DAHLER⁴, Stéphane BOLDUC⁵ and Soeren RITTIG⁶

¹ Astellas Pharma Europe BV, Global Medical Science - Urology / Nephrology, Leiden, NETHERLANDS

² Astellas Pharma Europe BV, Global Development Operations Biostatistics II, Leiden, NETHERLANDS

³ Astellas Pharma Europe BV, Global Development Operations, Clinical Science, Leiden, NETHERLANDS

⁴ Astellas Pharma BV, Global Development Operations Clinical Study Management, Leiden, NETHERLANDS

⁵ CHU de Québec, Division of Urology, Québec, CANADA

⁶ Aarhus University Hospital, Department of Pediatrics, Aarhus N, DENMARK

ICCS S2-2 (LO combined presentation with previous abstract)

SOLIFENACIN IN CHILDREN AND ADOLESCENTS WITH OVERACTIVE BLADDER: RESULTS OF AN OPEN-LABEL, LONG-TERM CLINICAL TRIAL

Brigitte BOSMAN¹, Donald NEWGREEN¹, Will SAWYER², Adriana HOLLESTEIN-HAVELAAR³, Ellen DAHLER³, Stéphane BOLDUC⁴ and Soeren RITTIG⁵

¹ Astellas Pharma Europe BV, Global Medical Science - Urology / Nephrology, Leiden, NETHERLANDS

² Astellas Pharma Europe BV, Global Development Operations Biostatistics II, Leiden, NETHERLANDS

³ Astellas Pharma Europe BV, Global Development Operations, Clinical Science, Leiden, NETHERLANDS

⁴ CHU de Québec, Division of Urology, Québec, CANADA

⁵ Aarhus University Hospital, Department of Pediatrics, Aarhus N, DENMARK

16:22-16:26

ICCS S2-3 (SO)

CHILDREN'S EXPERIENCES OF VOIDING SCHOOL INTERVENTION

Anneli SAARIKOSKI¹, Riitta KOPPELL² and Anna AXELIN³

¹ Helsinki University Hospital and University of Turku, Department of nursing science, The Hospital of Children and Adolescence, Helsinki, FINLAND

² Helsinki University Hospital, Jorvi Hospital, Espoo, FINLAND

³ University of Turku, Department of Nursing Science, Turku, FINLAND